Published online February 29, 2008
PEDIATRICS Vol. 121 No. 3 March 2008, pp. 562-569 (doi:10.1542/10.1542/peds.2007-0018)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adamkiewicz, T. V.
Right arrow Articles by Farley, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adamkiewicz, T. V.
Right arrow Articles by Farley, M. M.
Related Collections
Right arrow Infectious Disease & Immunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease in the First Decade of Life

Thomas V. Adamkiewicz, MD, MsCR, FRCP(C)a, Benjamin J. Silk, MPHb, James Howgate, MPHc, Wendy Baughman, MSAc, Gregory Strayhorn, MD, PhDa, Kevin Sullivan, PhDb and Monica M. Farley, MDc

a Department of Family Medicine, Morehouse School of Medicine, Atlanta, Georgia
b Rollins School of Public Health
c School of Medicine, Emory University, Atlanta, Georgia

BACKGROUND. The incidence of and mortality from invasive pneumococcal disease are significantly higher in children with sickle cell disease than in the general pediatric population. The objective of this population-based study was to assess the effect of pneumococcal conjugate vaccine on rates of invasive pneumococcal disease among children with sickle cell disease.

PATIENTS AND METHODS. Records, including the history of pneumococcal conjugate vaccine administration, of 1247 children born after 1983 residing in metropolitan Atlanta, Georgia, with confirmed hemoglobinopathies were linked to an active surveillance database for invasive pneumococcal disease for the period of January 1, 1995, through January 1, 2003. The incidence of invasive pneumococcal disease and the percentage of rate reduction were estimated before and after pneumococcal conjugate vaccine licensure. Survival analysis was used to estimate the effect of pneumococcal conjugate vaccine on invasive pneumococcal disease rates while accounting for herd immunity.

RESULTS. A significant decline in invasive pneumococcal disease in children with sickle cell disease ≤10 years of age was noted after pneumococcal conjugate vaccine licensure, from 1.7 infections per 100 person-years (1995–2000) to 0.5 infections per 100 person-years (2001–2002), which represents a 68% reduction. The effectiveness of ≥1 dose of pneumococcal conjugate vaccine was estimated by crude analysis to be 84.5% and by stratified survival analysis to be 81.4% when controlling for the presence of herd immunity in the 2 years after pneumococcal conjugate vaccine licensure. Serotype 6A invasive pneumococcal disease represented 36% of invasive pneumococcal disease before pneumococcal conjugate vaccine licensure and 0% after pneumococcal conjugate vaccine licensure, suggesting a protective effect against this pneumococcal conjugate vaccine-related serotype.

CONCLUSIONS. Invasive pneumococcal disease significantly decreased in children with sickle cell disease ≤10 years of age after pneumococcal conjugate vaccine licensure. Pneumococcal conjugate vaccine was effective even when controlling for herd immunity. Extending guideline recommendations for catch-up vaccination beyond 4 years of age should be considered.

Key Words: sickle cell anemia • hemoglobin SC disease • Streptococcus pneumoniae • sepsis • 7-valent PncOMPC vaccine; conjugate vaccine • herd immunity

Abbreviations: SCD—sickle cell disease • IPD—invasive pneumococcal disease • 23PS—23-valent pneumococcal polysaccharide vaccine • PCV—pneumococcal conjugate vaccine • EIP—Emerging Infections Program • SB0—S β-thalassemia 0 • NIS—National Immunization Survey • SB+—S β thalassemia + • CI—confidence interval

Accepted Sep 6, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
M Howard-Jones, L Randall, B Bailey-Squire, J Clayton, and N Jackson
An audit of immunisation status of sickle cell patients in Coventry, UK
J. Clin. Pathol., January 1, 2009; 62(1): 42 - 45.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
M. d. Montalembert
Management of sickle cell disease
BMJ, September 8, 2008; 337(sep08_1): a1397 - a1397.
[Full Text]